LEO 22811 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects

Trial Profile

LEO 22811 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs LEO 22811 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 21 Jan 2010 Actual patient number (58) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top